Previous 10 | Next 10 |
The following slide deck was published by Exagen Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Exagen Inc. 2022 Q2 - Results - Earnings Call Presentation
Gainers: Cooper-Standard Holdings ( CPS ) +78% . Highway Holdings ( HIHO ) +62% . Pineapple Energy ( PEGY ) +53% . Intelligent Living ( ILAG ) +55% . Progyny ( PGNY ) +41% . Global Blood Therapeutics ( GBT ) +38% . ...
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q2 2022 Earnings Call Aug 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q2 2022 Earnings Call Transcript
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the launch of a prospective clinical study designed to validate a novel and minimally invasive genomic diagnostic test for rheumatoid arthrit...
SAN DIEGO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights: Recognized total revenue of $9.0 million for...
SAN DIEGO, July 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 42 nd Annual Growth Conference, which takes place August 8-11, 2022, in Boston at the InterCon...
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended June 30, 2022, after the market close on Thursday, August 4, 2022. Ron Rocca, Exagen’s President ...
SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced new robust, real-world evidence confirming AVISE® testing enables decisive clinical action in the differential diagnosis for lupus. The Comple...
Exagen (NASDAQ:XGN) on Thursday said it had been added to MediNcrease Health Plans' national provider network. XGN said the addition will expand the coverage of the company's products to MediNcrease Health Plans' about 7.5M members. The agreement is effective July 1. As per the agreement, Med...
SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the addition of Exagen Inc. to MediNcrease Health Plans, LLC’s national provider network, providing enhanced care to their approximate...
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...